{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:23:05Z","timestamp":1783128185386,"version":"3.54.6"},"reference-count":79,"publisher":"Portland Press Ltd.","issue":"16","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fibrosis results from a disordered wound healing response within the liver with activated hepatic stellate cells laying down dense, collagen-rich extracellular matrix that eventually restricts liver hepatic synthetic function and causes increased sinusoidal resistance. The end result of progressive fibrosis, cirrhosis, is associated with significant morbidity and mortality as well as tremendous economic burden. Fibrosis can be conceptualized as an aberrant wound healing response analogous to a chronic ankle sprain that is driven by chronic liver injury commonly over decades. Two unique aspects of hepatic fibrosis \u2013 the chronic nature of insult required and the liver\u2019s unique ability to regenerate \u2013 give an opportunity for pharmacologic intervention to stop or slow the pace of fibrosis in patients early in the course of their liver disease. Two potential biologic mechanisms link together hemostasis and fibrosis: focal parenchymal extinction and direct stellate cell activation by thrombin and Factor Xa. Available translational research further supports the role of thrombosis in fibrosis. In this review, we will summarize what is known about the convergence of hemostatic changes and hepatic fibrosis in chronic liver disease and present current preclinical and clinical data exploring the relationship between the two. We will also present clinical trial data that underscores the potential use of anticoagulant therapy as an antifibrotic factor in liver disease.<\/jats:p>","DOI":"10.1042\/cs20191102","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T07:34:50Z","timestamp":1598427290000},"page":"2189-2201","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Healing gone wrong: convergence of hemostatic pathways and liver fibrosis?"],"prefix":"10.1042","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-7806","authenticated-orcid":false,"given":"Jessica\u00a0P.E.","family":"Davis","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen\u00a0H.","family":"Caldwell","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"2021113011152638300_B1","doi-asserted-by":"publisher","first-page":"759.e755","DOI":"10.1016\/j.cgh.2016.07.020","article-title":"Direct and Indirect Economic Burden of Chronic Liver Disease in the United States","volume":"15","author":"Stepanova","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2021113011152638300_B2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet (London, England)"},{"key":"2021113011152638300_B3","first-page":"31","article-title":"Cardiovascular dysfunction in patients with liver cirrhosis","volume":"28","author":"Fede","year":"2015","journal-title":"Ann. Gastroenterol."},{"key":"2021113011152638300_B4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"Gines","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2021113011152638300_B5","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1056\/NEJMra0707185","article-title":"Hepatopulmonary syndrome\u2013a liver-induced lung vascular disorder","volume":"358","author":"Rodriguez-Roisin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021113011152638300_B6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/hep.21101","article-title":"Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock","volume":"43","author":"Tsai","year":"2006","journal-title":"Hepatology"},{"key":"2021113011152638300_B7","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"2021113011152638300_B8"},{"key":"2021113011152638300_B9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"2021113011152638300_B10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1046\/j.1365-2168.2002.02166.x","article-title":"The mystery of liver regeneration","volume":"89","author":"Court","year":"2002","journal-title":"Br. J. Surg."},{"key":"2021113011152638300_B11","first-page":"721","article-title":"High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients","volume":"15","author":"Arab","year":"2016","journal-title":"Ann. Hepatol."},{"key":"2021113011152638300_B12","first-page":"1273","article-title":"Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes","volume":"151","author":"Overturf","year":"1997","journal-title":"Am. J. Pathol."},{"key":"2021113011152638300_B13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/lt.20096","article-title":"Liver regeneration after adult living donor and deceased donor split-liver transplants","volume":"10","author":"Humar","year":"2004","journal-title":"Liver Transpl."},{"key":"2021113011152638300_B14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","article-title":"Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c","volume":"34","author":"Poynard","year":"2001","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B15","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.3748\/wjg.v17.i45.5007","article-title":"Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation","volume":"17","author":"Maharshak","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"2021113011152638300_B16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jhep.2009.06.023","article-title":"Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease","volume":"51","author":"Papatheodoridis","year":"2009","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/gut.52.3.404","article-title":"Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis","volume":"52","author":"Papatheodoridis","year":"2003","journal-title":"Gut"},{"key":"2021113011152638300_B18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.20166","article-title":"Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C","volume":"39","author":"Poujol-Robert","year":"2004","journal-title":"Hepatology"},{"key":"2021113011152638300_B19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/gut.47.6.845","article-title":"The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985","volume":"47","author":"Yee","year":"2000","journal-title":"Gut"},{"key":"2021113011152638300_B20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2021113011152638300_B21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/ajg.2016.498","article-title":"Changing Concepts of Cirrhotic Coagulopathy","volume":"112","author":"Tripodi","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"2021113011152638300_B22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/gut.43.2.267","article-title":"Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding","volume":"43","author":"Chau","year":"1998","journal-title":"Gut"},{"key":"2021113011152638300_B23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/hep.510290437","article-title":"Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography","volume":"29","author":"Papatheodoridis","year":"1999","journal-title":"Hepatology"},{"key":"2021113011152638300_B24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jhep.2011.04.020","article-title":"Minimal effects of acute liver injury\/acute liver failure on hemostasis as assessed by thromboelastography","volume":"56","author":"Stravitz","year":"2012","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B25","volume-title":"Schiff's Diseases of the Liver","author":"Schiff","year":"2012","edition":"11th Edition"},{"key":"2021113011152638300_B26","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJM199306243282508","article-title":"Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies","volume":"328","author":"Friedman","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"2021113011152638300_B27","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2021113011152638300_B28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1055\/s-2001-17557","article-title":"Hepatic stellate cell behavior during resolution of liver injury","volume":"21","author":"Iredale","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"2021113011152638300_B29","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/TP.0b013e318168fcd4","article-title":"Coagulation defects do not predict blood product requirements during liver transplantation","volume":"85","author":"Massicotte","year":"2008","journal-title":"Transplantation"},{"key":"2021113011152638300_B30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1160\/TH16-06-0450","article-title":"The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis","volume":"117","author":"Ambrosino","year":"2017","journal-title":"Thromb. Haemost."},{"key":"2021113011152638300_B31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/ajg.2008.34","article-title":"Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study","volume":"104","author":"Sogaard","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"2021113011152638300_B32","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/j.1572-0241.2006.00588.x","article-title":"Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism","volume":"101","author":"Northup","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"2021113011152638300_B33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/hep.20569","article-title":"Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests","volume":"41","author":"Tripodi","year":"2005","journal-title":"Hepatology"},{"key":"2021113011152638300_B34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/BF01313579","article-title":"Bleeding after liver biopsy does not correlate with indices of peripheral coagulation","volume":"26","author":"Ewe","year":"1981","journal-title":"Dig. Dis. Sci."},{"key":"2021113011152638300_B35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5604\/01.3001.0010.8635","article-title":"Viscoelastic Testing in Liver Disease","volume":"17","author":"Davis","year":"2018","journal-title":"Ann. Hepatol."},{"key":"2021113011152638300_B36","first-page":"1232","article-title":"Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis)","volume":"21","author":"Wanless","year":"1995","journal-title":"Hepatology"},{"key":"2021113011152638300_B37","first-page":"1238","article-title":"Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension","volume":"21","author":"Wanless","year":"1995","journal-title":"Hepatology"},{"key":"2021113011152638300_B38","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/hep.1840030614","article-title":"The effect of mouse hepatitis virus infection on the microcirculation of the liver","volume":"3","author":"Levy","year":"1983","journal-title":"Hepatology"},{"key":"2021113011152638300_B39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/0026-2862(88)90014-3","article-title":"Microcirculatory changes in livers of mice infected with murine hepatitis virus. Evidence from microcorrosion casts and measurements of red cell velocity","volume":"36","author":"MacPhee","year":"1988","journal-title":"Microvasc. Res."},{"key":"2021113011152638300_B40","doi-asserted-by":"publisher","first-page":"G171","DOI":"10.1152\/ajpgi.00402.2017","article-title":"Role of the blood coagulation cascade in hepatic fibrosis","volume":"315","author":"Pant","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113011152638300_B41","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.clinre.2011.03.011","article-title":"The role of hypercoagulability in liver fibrogenesis","volume":"35","author":"Anstee","year":"2011","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"2021113011152638300_B42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep.20054","article-title":"PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation","volume":"39","author":"Fiorucci","year":"2004","journal-title":"Hepatology"},{"key":"2021113011152638300_B43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0168-8278(01)00285-9","article-title":"Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors","volume":"36","author":"Gaca","year":"2002","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B44","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"key":"2021113011152638300_B45","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/hep.24784","article-title":"Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells","volume":"55","author":"Knight","year":"2012","journal-title":"Hepatology"},{"key":"2021113011152638300_B46","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/hep.510270221","article-title":"Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury","volume":"27","author":"Marra","year":"1998","journal-title":"Hepatology"},{"key":"2021113011152638300_B47","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/jcp.21718","article-title":"Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase","volume":"219","author":"Bae","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"2021113011152638300_B48","doi-asserted-by":"publisher","first-page":"e86241","DOI":"10.1371\/journal.pone.0086241","article-title":"Proteinase activated receptor 1 mediated fibrosis in a mouse model of liver injury: a role for bone marrow derived macrophages","volume":"9","author":"Kallis","year":"2014","journal-title":"PLoS ONE"},{"key":"2021113011152638300_B49","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/hep.23435","article-title":"CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis","volume":"51","author":"Zaldivar","year":"2010","journal-title":"Hepatology"},{"key":"2021113011152638300_B50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.phrs.2004.04.009","article-title":"A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat","volume":"51","author":"Abdel-Salam","year":"2005","journal-title":"Pharmacol. Res."},{"key":"2021113011152638300_B51","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s10620-006-9595-1","article-title":"The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis","volume":"52","author":"Assy","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"2021113011152638300_B52","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jhep.2006.08.023","article-title":"Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat","volume":"46","author":"Abe","year":"2007","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12876-018-0789-8","article-title":"Thrombin and factor Xa link the coagulation system with liver fibrosis","volume":"18","author":"Dhar","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"2021113011152638300_B54","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S0168-8278(99)80284-0","article-title":"Treatment of concanavalin A-induced hepatitis in mice with low molecular weight heparin","volume":"31","author":"Hershkoviz","year":"1999","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B55","doi-asserted-by":"publisher","first-page":"23188","DOI":"10.1074\/jbc.M116.732743","article-title":"Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin","volume":"291","author":"Shearer","year":"2016","journal-title":"J. Biol. Chem."},{"key":"2021113011152638300_B56","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1038\/s41598-017-05190-7","article-title":"ENMD-1068 inhibits liver fibrosis through attenuation of TGF-beta1\/Smad2\/3 signaling in mice","volume":"7","author":"Sun","year":"2017","journal-title":"Sci. Rep."},{"key":"2021113011152638300_B57","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/toxsci\/kfw175","article-title":"From the Cover: Coagulation-Driven Hepatic Fibrosis Requires Protease Activated Receptor-1 (PAR-1) in a Mouse Model of TCDD-Elicited Steatohepatitis","volume":"154","author":"Nault","year":"2016","journal-title":"Toxicol. Sci."},{"key":"2021113011152638300_B58","doi-asserted-by":"publisher","first-page":"G226","DOI":"10.1152\/ajpgi.00444.2007","article-title":"Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis","volume":"294","author":"Rullier","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2021113011152638300_B59","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.2353\/ajpath.2010.100425","article-title":"The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis","volume":"177","author":"Sullivan","year":"2010","journal-title":"Am. J. Pathol."},{"key":"2021113011152638300_B60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/jth.12770","article-title":"Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice","volume":"13","author":"Joshi","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"2021113011152638300_B61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tox.2016.07.021","article-title":"Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease","volume":"365","author":"Joshi","year":"2016","journal-title":"Toxicology"},{"key":"2021113011152638300_B62","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1053\/j.gastro.2010.02.054","article-title":"Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice","volume":"138","author":"Kodama","year":"2010","journal-title":"Gastroenterology"},{"key":"2021113011152638300_B63","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13515","article-title":"Aspirin use is associated with lower indices of liver fibrosis among adults in the United States","volume":"43","author":"Jiang","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2021113011152638300_B64","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.clinre.2014.07.004","article-title":"Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation","volume":"38","author":"Poujol-Robert","year":"2014","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"2021113011152638300_B65","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/jnci\/djs452","article-title":"Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma","volume":"104","author":"Sahasrabuddhe","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"2021113011152638300_B66","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/apt.12944","article-title":"Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey","volume":"40","author":"Shen","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2021113011152638300_B67","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"Cerini","year":"2016","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B68","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.thromres.2008.11.008","article-title":"The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters","volume":"124","author":"Tripodi","year":"2009","journal-title":"Thromb. Res."},{"key":"2021113011152638300_B69","doi-asserted-by":"publisher","first-page":"e88390","DOI":"10.1371\/journal.pone.0088390","article-title":"Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis","volume":"9","author":"Potze","year":"2014","journal-title":"PLoS ONE"},{"key":"2021113011152638300_B70","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/j.1538-7836.2008.03015.x","article-title":"Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies","volume":"6","author":"Anstee","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"2021113011152638300_B71","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1111\/hae.13630","article-title":"Does haemophilia slow down the development of liver fibrosis?","volume":"25","author":"van Dievoet","year":"2019","journal-title":"Haemophilia: the Official J. World Federation of Hemophilia"},{"key":"2021113011152638300_B72","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/gut.52.8.1206","article-title":"Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection","volume":"52","author":"Wright","year":"2003","journal-title":"Gut"},{"key":"2021113011152638300_B73","doi-asserted-by":"publisher","first-page":"E335","DOI":"10.1002\/ajh.24427","article-title":"Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort","volume":"91","author":"Eyster","year":"2016","journal-title":"Am. J. Hematol."},{"key":"2021113011152638300_B74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jhep.2013.08.010","article-title":"Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders","volume":"60","author":"Fransen van de Putte","year":"2014","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B75","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-2141.1994.tb08312.x","article-title":"The progression of HCV-associated liver disease in a cohort of haemophilic patients","volume":"87","author":"Telfer","year":"1994","journal-title":"Br. J. Haematol."},{"key":"2021113011152638300_B76","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1440-1746.2007.05220.x","article-title":"Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis","volume":"23","author":"Martinelli","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2021113011152638300_B77","doi-asserted-by":"publisher","first-page":"S268","DOI":"10.1016\/S0168-8278(15)30165-3","article-title":"Thursz Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year","volume":"62","author":"Dhar","year":"2015","journal-title":"J. Hepatol."},{"key":"2021113011152638300_B78","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"2021113011152638300_B79","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig. Dis. Sci."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/16\/2189\/891605\/cs-2019-1102c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/16\/2189\/891605\/cs-2019-1102c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:13:39Z","timestamp":1638274419000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/134\/16\/2189\/226195\/Healing-gone-wrong-convergence-of-hemostatic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":79,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,8,28]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20191102","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,8]]}}}